ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor. Preliminary safety and efficacy of tinengotinib tablets as monotherapy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results